Register for free to listen to this article
Listen with Speechify
0:00
2:00
BASEL, Switzerland—On May 18, Swiss pharmaceutical and life science product provider Lonza Group Ltd. completed its acquisition of MODA Technology Partners, a Wayne, Pa.-based developer of informatics solutions for the pharmaceutical and biotechnology quality manufacturing industries, for an undisclosed sum.

Lonza said the acquisition, initially announced May 12, continues the expansion of its Rapid Testing Solutions platforms, which enable same-day approaches to product and environmental testing, in both existing and new markets. Lonza's platforms currently include Endotoxin Detection, Informatics, Microbiology and Global Support.

Doug Danne, head of Lonza's Rapid Testing Solutions business unit, said in a statement that the company identified MODA's technology as a result of its own internal need to seek out automated tools that would help improve productivity and regulatory compliance. MODA's technology provides paperless, quality-control solutions for regulated, manufacturing processes. The technology can be applied to clinical trials, in vitro diagnostics, environmental and industrial process markets worldwide. The company bills its flagship software, MODA-EM, as a paperless quality-control microsolution that leverages mobile computing technology and advanced visualization tools for increased operational efficiency, improved quality and reduced costs.

The "MODA-EM informatics platform offered intelligent, real-time solutions and user-friendly trending tools that improved our return on investment," Danne stated. "Lonza provided a unique resource of being an expert user of the product, and we are excited to explore new applications of MODA's mobile data acquisition technology, both internally at Lonza, as well as for our external customers."

The implementation of MODA's technology will begin at Lonza's manufacturing locations globally. Going forward, customer sites will be fully supported through Lonza's Global Solutions Support team, offering hands-on installation, accelerated validation as well as training services.

"We are very excited to be part of the Lonza family," said MODA CEO Mike Desiderio in a statement. "Our shared vision for a comprehensive analytics platform is now a reality, providing the industry a clear path to enhanced compliance, improved efficiencies and expedited decision-making."
 
Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue